Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729924 · ClinicalTrials.gov registry record · Phase 2
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00729924 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 40 participants.
The verdict
NCT00729924, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.
Interventions
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729924
The ClinicalTrials.gov registry entry for NCT00729924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir is the first listed.
NCT00729924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729924 about?
NCT00729924 is a clinical study titled "Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid". This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.
What is the current status of trial NCT00729924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00729924?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00729924?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.